Sugi Predict

Sugi Predict / Compounds / SCHEMBL29832891

SCHEMBL29832891

SCHEMBL29832891

CC(C)(C)OC(=O)N1CCC2(CC1)Cc1ccccc1/C2=N/[S@+]([O-])C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.39
▸ CHRM4 P08173 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ USP30 Q70CQ3 1/20 0.39
▸ TSHR P16473 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ HDAC1 Q13547 2/20 0.37
▸ HDAC8 Q9BY41 2/20 0.37
▸ HDAC6 Q9UBN7 2/20 0.37
▸ GPR119 Q8TDV5 2/20 0.37
▸ PDK2 Q15119 1/20 0.37
▸ NAMPT P43490 2/20 0.37
▸ USP1 O94782 1/20 0.36
▸ SMARCA2 P51531 1/20 0.36
▸ SMARCA4 P51532 1/20 0.36
▸ PBRM1 Q86U86 1/20 0.36
▸ TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29399249 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL30040600 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL30110916 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL22774338 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL31050860 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL22440590 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL24097165 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL22793052 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL21852133 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1
SCHEMBL22309387 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO LTD (CN) 2025-07-10 — — US disclosed
US-20250066357-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-02-27 — — US disclosed
US-12187721-B2 Protein tyrosine phosphatase inhibitors ARRAY BIOPHARMA INC. (US) 2025-01-07 — — US disclosed
EP-3601239-B1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO LTD (CN) 2024-07-31 — — EP disclosed
US-20240124453-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2024-04-18 — — US disclosed
US-11884664-B2 Protein tyrosine phosphatase inhibitors ARRAY BIOPHARMA INC. (US) 2024-01-30 — — US disclosed
EP-3867238-B1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC (US) 2023-06-07 — — EP disclosed
US-20230134869-A1 CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2023-05-04 — — US disclosed
US-11634417-B2 Protein tyrosine phosphatase inhibitors ARRAY BIOPHARMA INC. (US) 2023-04-25 — — US disclosed
EP-4129987-A1 CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES Shanghai Hansoh Biomedical Co., Ltd. (CN) 2023-02-08 — — EP disclosed
CN-115353509-A Aza-containing aromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2022-11-18 — — CN disclosed
CN-111295374-B Aza-containing aromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2022-11-04 — — CN disclosed
CN-115052866-A Crystal form of free base of nitrogen-containing heteroaromatic derivative 上海翰森生物医药科技有限公司 2022-09-13 — — CN disclosed
US-20220251083-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066357-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C CHRM2 4841/4885CHRM4 4843/4885CHRM1 4741/4885
US-11884664-B2 Protein tyrosine phosphatase inhibitors PPM1A, PPM1F, PPP5C CHRM2 4841/4885CHRM4 4837/4885CHRM1 4737/4885
US-12187721-B2 Protein tyrosine phosphatase inhibitors PPM1A, PTP4A1, PPP5C CHRM2 4837/4885CHRM4 4832/4885CHRM1 4728/4885
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ CHRM2 4862/4885CHRM4 4837/4885CHRM1 4870/4885
US-20240124453-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C CHRM2 4841/4885CHRM4 4837/4885CHRM1 4737/4885
US-11634417-B2 Protein tyrosine phosphatase inhibitors PPM1A, PPM1F, PPP5C CHRM2 4841/4885CHRM4 4837/4885CHRM1 4737/4885
US-20220251083-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C CHRM2 4841/4885CHRM4 4837/4885CHRM1 4737/4885
US-20230134869-A1 CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES PTPN22, PTPN2, PTPN5 CHRM2 3665/4885CHRM4 4532/4885CHRM1 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.